Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 1, 2023
Discovery & Translation

CorrectSequence’s hemoglobin base editor; plus Denali’s LXR agonist and more

BioCentury’s roundup of translational innovations
BioCentury | Aug 23, 2023
Distillery Therapeutics

Engineered oncolytic virus expressing APOA1 for glioblastoma

BioCentury | Feb 2, 2018
Translation in Brief

Untangling MS

How screening cell by cell could help target MS disability by disability
BioCentury | Feb 1, 2018
Distillery Therapeutics

Autoimmune disease

BioCentury | May 31, 2017
Distillery Techniques

Disease models

BioCentury | Jul 27, 2015
Clinical News

MDCO-216: Phase I data

BioCentury | Mar 27, 2015
Financial News

Cerenis raises EUR 53.4M in Euronext IPO

BioCentury | Sep 15, 2014
Clinical News

Cerenis HDL regulatory update

BioCentury | Oct 10, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

BioCentury | Apr 18, 2013
Distillery Therapeutics

Indication: Ophthalmic disease

Items per page:
1 - 10 of 21
Help Center
Username
Request a Demo
Request Training
Ask a Question